// App-Quantinova.ai

4710 : BRD4 degradation by PROTACs represents a more effective therapeutic strategy than BRD4 inhibitors in ovarian cancer

Researchers

Presenter

  • Kanak Raina

Principal Investigators

  • Jing Lu

  • Yimin Qian

  • Martha Altieri

  • Hanqing Dong

  • Jing Wang

  • Xin Chen

  • Andrew Crew

  • Kevin Coleman

  • Craig Crews

  • James Winkler

Medical Centers

  • Arvinas, Inc, New Haven, CT.

  • Yale University, New Haven, CT

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • High grade serous ovarian cancer

  • Gynaecological cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved